Management should follow a treat-to-target strategy aimed at achieving clinical and, when feasible, imaging remission. Although glucocorticoids remain the cornerstone of treatment, steroid-sparing approaches, particularly with tocilizumab, and emerging targeted biotherapies may improve long-term vascular outcomes and prognosis in selected patients.
Secada-Gómez et al. (Mon,) studied this question.